On March 9, 2022 Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immune-therapeutics based on Seneca Valley Virus (SVV-001), reported the publication of an abstract "Oncolytic Seneca Valley Virus (SVV-001) overcomes checkpoint inhibitor resistance and demonstrates a systemic anti-tumor immune response in a syngeneic pancreatic cancer murine model" at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting in New Orleans, LA (Press release, Seneca Therapeutics, MAR 9, 2022, View Source [SID1234609815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract will be presented by Dr. Paul Hallenbeck, one of the authors of the publication. The permanent abstract number is #6218. The presentation will be available starting April 8.

On March 9, 2022 Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, reported plans to present at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022 (Press release, Boundless Bio, MAR 9, 2022, View Source [SID1234609814]). The in-person poster presentation reveals a novel association between ecDNA bearing tumors and high replication stress, presenting a potential therapeutic strategy for ecDNA-enabled oncogene amplified cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Title: Replication stress and the inability to repair damaged DNA, the potential "Achilles’ heel" of ecDNA+ tumor cells
Session Title: Genomic Instability 2
Abstract Number: 1520
Date and Time: April 11, 2022, 1:30 p.m. – 5:00 p.m. ET
Location: Poster Section 5

About ecDNA

Extrachromosomal DNA ("ecDNA") are circular units of nuclear DNA found within cancer cells, and which contain highly transcriptionally active genes, including oncogenes, but are physically distinct from chromosomes and lack centromeres. ecDNA replicate within cancer cells and, due to their lack of centromeres, can be asymmetrically passed to daughter cells during cell division, leading to focal gene amplification and copy number heterogeneity in cancer. By leveraging the plasticity afforded by ecDNA, cancer cells have the ability to increase or decrease copy number of select oncogenes located on ecDNA to enable survival under selective pressures, including targeted therapy, immunotherapy, chemotherapy, or radiation, thereby making ecDNA one of cancer cells’ primary mechanisms of growth, recurrence, and treatment resistance. ecDNA are not found in healthy cells but are present in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.

On March 9, 2022 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, reported that management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022 at 4:00 p.m. ET (Press release, Wugen, MAR 9, 2022, View Source [SID1234609813]). The presentation will be available to registered conference attendees.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 9, 2022 Palleon Pharmaceuticals, a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, reported two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans, La., from April 8-13, 2022 (Press release, Palleon Pharmaceuticals, MAR 9, 2022, View Source [SID1234609812]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Palleon will present an assessment of the safety, pharmacokinetics, and pharmacodynamics of E-602, the company’s first-in-class immuno-oncology drug candidate, in non-human primates. Those studies found that E-602 exhibits sustained, dose-dependent pharmacodynamic effects on desialylation of immune cells and a wide safety margin.

Additionally, Palleon will present data on the company’s novel bifunctional PD-L1-targeted sialidase. Studies performed in a transgenic mouse model of colon cancer expressing PD-L1 found that the bifunctional PD-L1-targeted sialidase exhibited enhanced efficacy compared to E-602 and to an anti-PD-L1 antibody, as well as dose-dependent tumor growth inhibition and modulation of immune cell infiltration.

Details of the poster presentations are as follows:

Title: Assessment of the safety, pharmacokinetics, and pharmacodynamics of a first-in-class cancer drug candidate E-602, a sialoglycan degrader, in non-human primates
Number: LB203
Timing: April 13, 2022, 9:00 a.m. – 12:30 p.m. CDT

Title: Development of PD-L1-targeted sialidase as a novel cancer immunotherapeutic approach
Number: LB221
Timing: April 13, 2022, 9:00 a.m. – 12:30 p.m. CDT

On March 9, 2022 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, reported that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three investor conferences in March 2022 (Press release, Fortress Biotech, MAR 9, 2022, View Source [SID1234609811]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

34th Annual ROTH Conference: The company will participate in a fireside chat on Monday, March 14, 2022, at 3:00 p.m. PT and will attend one-on-one meetings during the conference. A webcast of the fireside chat will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the chat.
Oppenheimer’s 32nd Annual Virtual Healthcare Conference: The company will present on Wednesday, March 16, 2022, at 8:40 a.m. ET and will participate in one-on-one meetings during the conference. A webcast of the presentation will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the meeting.
Cantor Fitzgerald’s Rare Orphan Disease Summit: The company will participate in a panel presentation on Wednesday, March 30, 2022, at 8:30 a.m. ET, titled, "Beyond The One-Hit Wonder: How To Build A Rare Disease Pipeline."